Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

Evaluation of the Removal of Excess Intra-Abdominal Fat in Subjects With Type 2 Diabetes and Obesity, Using the HydraSolve T2D™ System, on Glucose Control, Insulin Resistance and Body Weight

This study will investigate the safety and efficacy of the investigational use of the HydraSolve T2D™ System in improving blood glucose control and insulin resistance in patients with obesity (Class 1, BMI 30-39.9 kg/m2) and type 2 diabetes who have not achieved targeted levels of blood glucose control using oral diabetes medications. The previously FDA-cleared (for liposuction and fat transfer) HydraSolve T2D™ System will be used to perform a novel, minimally invasive laparoscopic and mini-laparotomy procedure to selectively remove excess intra-abdominal fat from the mesentery (Mesenteric Visceral Lipectomy (MVL)), while not affecting surrounding tissues. The study will include several weeks of screening for eligibility before the intervention, and 12-months of follow-up post-surgery.

Study Overview

• Status: Recruiting
• Conditions: Diabetes Mellitus, Type 2; Insulin Resistance
• Intervention / Treatment: Device: HydraSolve T2D™

Detailed Description

This study will evaluate the investigational use of the HydraSolve T2D™ System (previously FDA-cleared for liposuction and fat transfer) to perform a novel, minimally invasive laparoscopic and mini-laparotomy procedure to selectively remove intra-abdominal fat from the mesentery and to assess the resulting changes in blood glucose control, insulin sensitivity and body weight. Excess intra-abdominal mesenteric fat has been directly linked to insulin resistance, an important precursor of type 2 diabetes. Up to 30 study candidates will undergo screening and eligibility testing over a 5-week period from which 12 will be enrolled to undergo the procedure. During the 12-month period post-procedure, the patients will be periodically monitored for improvements in blood glucose control (HbA1c, oral glucose tolerance test (OGTT), fasting blood glucose (FBG) and continuous glucose monitoring (CGM)), insulin resistance (hyperinsulinemic euglycemic glucose clamp), body weight, changes in fat deposits (Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) and Dual-Energy X-ray Absorptiometry (DEXA)) and overall metabolic health (including indirect calorimetry and various biomarkers). This prospective, single-arm study uses pre-operative patient data as the control. Safety assessments and monitoring for adverse events will be performed, throughout.

• Study Type: Interventional
• Enrollment (Anticipated): 12
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Mark Andrew, MD; Phone Number: 856-701-2680; Email: Mark.Andrew@MedalityMedical.com

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78229
      • Recruiting
      • University of Texas Health Science Center at San Antonio
      • Contact: Ralph A DeFronzo, MD; Phone Number: 210-567-6691; Email: defronzo@uthscsa.edu
      • Contact: Monica Palomo, BS; Phone Number: 210-567-6710; Email: palomom@uthscsa.edu
      • Principal Investigator: Ralph A DeFronzo, MD
      • Sub-Investigator: Richard Peterson, MD
      • Sub-Investigator: Eugenio Cersosimo, MD PhD
      • Sub-Investigator: Carolina Solis-Herrera, MD
      • Sub-Investigator: Alberto Chavez-Velasquez, MD
      • Sub-Investigator: Mohamed Eletrebi, MD
      • Sub-Investigator: Curtiss Puckett, PA
      • Sub-Investigator: Andrea Hansis-Diarte, MPH
      • Sub-Investigator: Sara Olivarri, BSN

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 1. Willingness to provide written informed consent.

  2. Willingness and availability to comply with study requirements for the duration of the study, including specific inquiry that the potential subject does not have an impending move or travel planned and can attend the patient visits without undue hardship.

  3. Male or female between 22 - 75 years of age. (Caveat: premenopausal women are excluded)

  4. In good general health except for being diagnosed as having T2D,and in good enough general health to undergo a conversion from a mini-laparotomy to an open laparotomy incision if that conversion becomes necessary during the operative procedure; the subject has no major system disease other than T2D as determined by physical examination, medical history, screening laboratory tests, and EKG.

  5. BMI 30 to 39.9 kg/m2.

  6. Stable body weight during the 6 month time period preceding the anticipated surgery date. (Stable is defined as: the usual baseline body weight of the subject +/- < 5% change.)

  7. Diagnosis of T2D 10 years or less in duration.

  8. Subject has poorly controlled T2D and is on a current regimen of at least two oral hypoglycemic agents, the first medication dosed at the maximum dose, and the second dosed at the minimum or higher labelled dose. Subject's treatment regime does not include insulin treatment.

  9. HbA1c: 8.0 % - 10.0 %, taken within 30 days pre-op.

  10. Subjects receiving exogenous thyroid hormone, a euthyroid status for at least 3 months prior to enrollment needs to be documented.

  11. Subject agrees to not take any medications that can influence glycemic control unless directed to do so specifically by their physician.

  12. Subject agrees to report all medications they are taking on all case report forms.

  13. Subject agrees to not take any herbal or dietary supplements during the study period.

  14. Subject agrees to not donate blood during the study period.

  15. Subject resides in the San Antonio, TX geographic area.

  16. Subject is able to have MRI examinations.

Exclusion Criteria:

• 1. Premenopausal females.

  2. Tobacco use.

  3. Current drug or ETOH abuse.

  4. Uncontrolled psychiatric illness.

  5. Abnormal T4 and TSH found in screening blood test.

  6. Subjects who have contraindications to major abdominal surgery are excluded.

  7. Serum albumin <35 g/L

  8. Body weight loss >5% during the 6 month time period preceding the anticipated surgery date.

  9. Presence of a remote body site infection. (Examples: dental urinary, skin soft tissue)

  10. History of cholecystitis, hepatitis or NASH.

  11. History of ulcerative colitis, Crohn's disease, or diverticulitis.

  12. History of respiratory conditions that are not controllable without the use of chronic or intermittent steroid use; such as poorly controlled asthma or COPD.

  13. Chemistry, liver enzyme and function, and hematology levels that are outside of the normal range. (Fasting glucose may be elevated but subject will be excluded if it is ≥ 250 mg/dl.)

  14. LDL ≥ 180 mg/dl.

  15. Triglycerides ≥ 400 mg/dl.

  16. A diagnosis of Cushing's disease. (If a potential subject does not have a diagnosis of Cushing's disease, and the examining endocrinologist detects concerning signs or symptoms that lead him/her to suspect that the potential subject may have Cushing's disease (based on the subject's history, review of systems and physical exam) then that potential subject will be excluded from the study and referred back to his/her primary care physician for further evaluation.)

  17. Anemia, hemoglobinopathy or any conditions that increase red blood cell turnover.

  18. Recent history of receiving a blood transfusion.

  19. Recent history of donating blood.

  20. Clinically significant major organ disease as determined by medical history, physical exam, screening blood tests, urinalysis, and EKG.

  21. History of prior abdominal/pelvic surgery, or prior OB/GYN surgery.

  22. Uncontrolled comorbidity. (Example: uncontrolled hypertension.)

  23. Large umbilical hernia. (This does not include small umbilical hernias that are fat containing only; subjects with this specific type of hernia are allowed in the study, and this type of hernia could be managed and closed primarily with closure of the surgical site.)

  24. Large ventral hernia.

  25. Use of insulin.

  26. Anticoagulation or antiplatelet therapies.

  27. History of gastrointestinal cancer.

  28. Limited life expectancy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intra-Abdominal Mesenteric Fat Extraction Group; All enrolled patients will undergo the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery.	Device: HydraSolve T2D™; The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in blood glucose control	Change in blood glucose control, as measured by the average of two HbA1c values at 6-months and 12-months post-procedure and at other time points, compared to the average of two HbA1c values 1-month pre-procedure.	6 and 12 months after the procedure
Lack of serious adverse events (SAEs)	Lack of serious adverse events (SAEs) assessed continuously during or after the procedure	Through 1 year study completion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Insulin Sensitivity	Change in insulin sensitivity as measured by hyperinsulinemic euglycemic clamp at 6 and 12 months, as compared to pre-procedure	6 and 12 months after the procedure
Change in blood glucose control	Change in blood glucose control (time in range, etc.) as measured by Continuous Glucose Monitoring (CGM) pre-procedure, and at 1-week, 3, 6 and 12-months post procedure	1-week, 3, 6, and 12-months post procedure
Change in fasting plasma glucose (FPG)	Change in fasting plasma glucose (FPG) and mean glycemic excursion as measured by oral glucose tolerance test (OGTT) pre-procedure and 1, 3, 6 and 12-months post procedure	1, 3, 6, and 12-month post procedure
Reduction in body weight	Reduction in body weight measured at each clinic visit	1, 2, 3, 4, 10, 12, 18 weeks, and 6, 8, 10, 12 months post procedure

Collaborators and Investigators

• Sponsor: Medality Medical
• Investigators: Principal Investigator: Ralph DeFronzo, MD, University of Texas; Study Director: Mark Andrew, MD, Medality Medical

Publications and helpful links

General Publications

• Andrew MS, Huffman DM, Rodriguez-Ayala E, Williams NN, Peterson RM, Bastarrachea RA. Mesenteric visceral lipectomy using tissue liquefaction technology reverses insulin resistance and causes weight loss in baboons. Surg Obes Relat Dis. 2018 Jun;14(6):833-841. doi: 10.1016/j.soard.2018.03.004. Epub 2018 Mar 9.

Study record dates

Study Major Dates

• Study Start (Actual): October 18, 2019
• Primary Completion (Anticipated): July 30, 2021
• Study Completion (Anticipated): March 15, 2022

Study Registration Dates

• First Submitted: May 12, 2019
• First Submitted That Met QC Criteria: May 15, 2019
• First Posted (Actual): May 17, 2019

Study Record Updates

• Last Update Posted (Actual): March 18, 2021
• Last Update Submitted That Met QC Criteria: March 16, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: Diabetes; Obesity; Diabetes Mellitus; Insulin Resistance; Type 2 diabetes; Noninsulin-Dependent Diabetes Mellitus; Glucose Metabolism Disorder; Mesenteric Visceral Fat; Diabesity; HydraSolve T2D
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Hyperinsulinism; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance
• Other Study ID Numbers: CIP-00001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: The research team will send deidentified study results to Medality Medical

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes